Cas no 73536-69-3 (Bifendate)
Bifendate Chemical and Physical Properties
Names and Identifiers
-
- Bifendate
- 4'-bi-1,3-benzodioxole)-5,5'-dicarboxylicacid,7,7'-dimethoxy-(dimethyles
- dimethyl4,4'-dimethoxy-5,6,5',6'-bis(methylenedioxy)biphenyl-2,2'-dicarboxyl
- dimethyl7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylate
- dimethyl 4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate
- 4,4-DIMETHOXY-5,5',6,6'-DI(METHOXYMETHENYL)-2,2-DIMETHOXY CARBOXYLBIPHENYL
- 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester
- Bdd(bifendate)
- Bifendatatum
- Bifendatatum (B.D.D)
- BIFENDATATUM (B.D.D) PHARMACEUTICAL GRADE
- methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate
- dimethyl 4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenylbiphenyl-2,2'-dicarboxylate
- Dimethyl 7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate
- dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dicarboxybiphenyl-2,2'-dicarboxylate
- alpha-Diphenyldicarboxylate
- Bifendate,(S)
- C20H18O10
- 0G32E321W1
- Dimethyl-4,4'-dimethoxyl-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate
- Dimethyl 7,7'-dimethoxy-(4,4'-Bi-1,3-benzodioxole)-5,5'-dicarboxylate
- Dimethyl 4,4'-dimethoxy-5,6,5',6'-bis(methylenedioxy)biphenyl-2,2'-dicarboxylate
- DTXSID40223736
- CCRIS 7767
- CCG-268865
- diphenyl dimethyl dicarboxylate
- BIFENDATE [WHO-DD]
- [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylic acid, 7,7'-dimethoxy-, dimethyl ester, (R)-
- PP685NHP9Z
- CE2LBA6CBR
- SY021274
- BRN 5461320
- [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylic acid, 7,7'-dimethoxy-,dimethyl ester
- Q27236735
- 111897-25-7
- dimethyl diphenyl bicarboxylate
- HY-W018791
- Bifendate, (R)-
- Dimethyl dicarboxylate biphenyl
- (4,4'-BI-1,3-BENZODIOXOLE)-5,5'-DICARBOXYLIC ACID, 7,7'-DIMETHOXY-, 5,5'-DIMETHYL ESTER
- NS00116009
- DIMETHYL-4,4'-DIMETHOXY-5,6,5',6'-DIMETHYLENEDIOXYBIPHENYL-2,2'-DICARBOXYLATE
- Dimethyl 7 pound not7'-dimethoxy-[4 pound not4'-bibenzo[d][1 pound not3]dioxole]-5 pound not5'-dicarboxylate
- Diphenyl dimethyl bicarboxylate
- s4890
- SCHEMBL896166
- Dimethyl7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate
- [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylic acid, 7,7'-dimethoxy-, dimethyl ester, (4S)-
- [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylic acid, 7,7'-dimethoxy-, dimethyl ester, (4R)-
- UNII-0G32E321W1
- A866077
- CHEMBL105184
- 2,2'-Dimethoxycarbonyl-4,4'-dimethoxy-5,6,5',6'-bismethylenedioxybiphenyl
- MFCD01751431
- BDBM50289527
- FT-0602821
- Dimethyl 7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate
- BCP12613
- (4,4'-Bi-1,3-benzodioxole)-5,5'-dicarboxylic acid, 7,7'-dimethoxy-, dimethyl ester
- 73536-69-3
- 111897-26-8
- Dimethyl 7,7 inverted exclamation mark -Dimethoxy-[4,4 inverted exclamation mark -bi-1,3-benzodioxole]-5,5 inverted exclamation mark -dicarboxylate
- Bifendate, (S)-
- .alpha.-ddb
- AKOS015895317
- B6112
- biphenyl dimethyl-dicarboxylate
- SB67338
- AS-13115
- CS-W019577
- [4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylic acid, 7,7'-dimethoxy-, dimethyl ester, (S)-
- DDB
- BRD-K26581543-001-01-6
- DTXCID70146227
- 7,7'-dimethoxy-5,5'-bis(methoxycarbonyl)-4,4'-bis(1,3-benzodioxole)
- AN-786/13677002
- ALPHA-DDB
-
- MDL： MFCD01751431
- Inchi： 1S/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3
- InChI Key： JMZOMFYRADAWOG-UHFFFAOYSA-N
- SMILES： O1COC2=C(C=C(C(=O)OC)C(=C12)C1C(C(=O)OC)=CC(=C2C=1OCO2)OC)OC
- BRN： 5461320
Computed Properties
- Exact Mass: 418.09000
- Monoisotopic Mass: 418.09
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 10
- Heavy Atom Count: 30
- Rotatable Bond Count: 7
- Complexity: 587
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 108
- XLogP3: 2.8
Experimental Properties
- Density: 1.39
- Boiling Point: 606.9°C at 760 mmHg
- Flash Point: 265.9°C
- Refractive Index: 1.579
- PSA: 107.98000
- LogP: 2.40140
Bifendate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Fluorochem | 077082-10g |
Bifendatatum |
73536-69-3 | 95% | 10g |
￡25.00 | 2022-03-01 | |
| Fluorochem | 077082-25g |
Bifendatatum |
73536-69-3 | 95% | 25g |
￡51.00 | 2022-03-01 | |
| Chemenu | CM254812-25g |
Dimethyl 7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate |
73536-69-3 | 98% | 25g |
$148 | 2021-06-17 | |
| Chemenu | CM254812-100g |
Dimethyl 7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate |
73536-69-3 | 98% | 100g |
$421 | 2021-06-17 | |
| S e l l e c k ZHONG GUO | S4890-100mg |
Bifendate |
73536-69-3 | 99.94% | 100mg |
￥795.08 | 2023-09-15 | |
| Alichem | A159001486-25g |
Dimethyl 7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate |
73536-69-3 | 98% | 25g |
$308.00 | 2023-09-01 | |
| Alichem | A159001486-100g |
Dimethyl 7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5,5'-dicarboxylate |
73536-69-3 | 98% | 100g |
$740.94 | 2023-09-01 | |
| TRC | B382890-1g |
Bifendate |
73536-69-3 | 1g |
$ 150.00 | 2023-04-18 | ||
| TRC | B382890-10g |
Bifendate |
73536-69-3 | 10g |
$ 572.00 | 2023-04-18 | ||
| TRC | B382890-25g |
Bifendate |
73536-69-3 | 25g |
$ 894.00 | 2023-04-18 |
Bifendate Suppliers
Audited Supplier
Audited Supplier
Bifendate Related Literature
-
Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
-
2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
-
Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
-
Marta Liras,Isabel Quijada-Garrido,Marta Palacios-Cuesta,Sonia Mu?oz-Durieux,Olga García Polym. Chem., 2014,5, 433-442
-
Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
Additional information on Bifendate
Introduction to Bifendate (CAS No: 73536-69-3) in Modern Pharmaceutical Research
Bifendate, a compound with the chemical identifier CAS No: 73536-69-3, has emerged as a significant molecule in the field of pharmaceutical research and development. This compound, belonging to the class of synthetic organic chemicals, has garnered attention due to its unique pharmacological properties and potential applications in therapeutic interventions. The growing interest in Bifendate is not only attributed to its structural characteristics but also to its demonstrated efficacy in various preclinical and clinical studies.
The chemical structure of Bifendate encompasses specific functional groups that contribute to its pharmacodynamic behavior. These functional groups enable the compound to interact with biological targets, modulating cellular processes and physiological pathways. Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of how Bifendate interacts with its intended biological targets, providing insights into its mechanism of action.
In the realm of academic research, Bifendate has been extensively studied for its potential role in addressing various health conditions. One of the most compelling areas of research involves its application in gastrointestinal health. Studies have indicated that Bifendate possesses properties that can help alleviate symptoms associated with certain gastrointestinal disorders. This has led to investigations into its potential as a therapeutic agent for conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).
Furthermore, the compound has shown promise in combating antibiotic-resistant bacteria. In an era where antibiotic resistance is becoming increasingly prevalent, the development of novel antimicrobial agents is crucial. Research has demonstrated that Bifendate exhibits activity against a range of Gram-positive bacteria, making it a candidate for inclusion in combination therapies aimed at eradicating resistant strains.
The pharmacokinetic profile of Bifendate is another area of significant interest. Studies have revealed that the compound exhibits good oral bioavailability and a favorable half-life, suggesting its potential for effective dosing regimens. This characteristic is particularly important for patient compliance and therapeutic efficacy. Additionally, preliminary toxicology studies have indicated that Bifendate is well-tolerated at recommended doses, further supporting its potential as a safe and effective therapeutic option.
Recent clinical trials have begun to explore the therapeutic potential of Bifendate in humans. These trials are focusing on conditions where current treatments are limited or where there is a high unmet medical need. The results from these trials are expected to provide valuable data on the safety and efficacy of Bifendate in human populations, paving the way for possible regulatory approval and commercialization.
The development of Bifendate also highlights the importance of interdisciplinary collaboration in pharmaceutical research. The integration of expertise from chemistry, biology, pharmacology, and clinical medicine has been instrumental in advancing our understanding of this compound. Such collaborative efforts are essential for translating laboratory discoveries into tangible therapeutic benefits for patients.
Looking ahead, the future prospects for Bifendate appear promising. Ongoing research is aimed at optimizing its chemical structure to enhance its pharmacological properties further. Additionally, exploring new applications for Bifendate in other therapeutic areas could expand its medical utility significantly. The continued investment in research and development will be crucial in realizing the full potential of this compound.
In conclusion, Bifendate (CAS No: 73536-69-3) represents a significant advancement in pharmaceutical science. Its unique chemical properties, coupled with promising results from preclinical and clinical studies, position it as a compelling candidate for therapeutic intervention. As research progresses, we can anticipate further revelations about its potential applications and mechanisms of action, contributing to improved healthcare outcomes.
73536-69-3 (Bifendate) Related Products
- 133920-93-1(1,3-Benzodioxole-5-carboxylic acid,4-[4,5-dimethoxy-2-[(2-methylphenoxy)carbonyl]phenyl]-)
- 120139-69-7([1]Benzopyrano[5,4,3-cde][1,3]dioxolo[4,5-h][1]benzopyran-5,11-dione,1,2,3,6-tetramethoxy- (9CI))
- 156809-09-5(1,3-Benzodioxole-5-carboxylicacid, 4-[6-(ethoxycarbonyl)-2,3,4-trimethoxyphenyl]-, ethyl ester)
- 69251-99-6([1]Benzopyrano[5,4,3-cde][1,3]dioxolo[4,5-h][1]benzopyran-5,11-dione,1,2,3-trimethoxy-)
- 56470-19-0(3'-O-methyl-3,4-di-O-methylenedioxyellagic acid)
- 145726-39-2(Justicidin H)
- 118159-48-1(Bicyclol)
- 73428-14-5(Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(8H)-one, 9-(6-hydroxy-1,3-benzodioxol-5-yl)-)
- 91828-88-5([4,4'-Bi-1,3-benzodioxole]-5,5'-dicarboxylicacid, 7-hydroxy-7'-methoxy-, 5,5'-dimethyl ester)
- 105868-34-6(Bifendate Dicarboxylic Acid)
